IOVA vs IVVD

Iovance Biotherapeutics, Inc. vs Invivyd, Inc. — Valuation Comparison 2026

IOVA

Biotechnology
Iovance Biotherapeutics, Inc.
Quality
5.1
out of 10
Value Trap
18
SAFE
Price
$4.30
Last close
Models
11/13
Active
VS

IVVD

Biotechnology
Invivyd, Inc.
Quality
4.3
out of 10
Value Trap
24
SAFE
Price
$1.13
Last close
Models
4/13
Active

Model-by-Model Comparison

ModelType IOVA Fair ValueIOVA Upside IVVD Fair ValueIVVD Upside
Bayesian DCF Intrinsic $1.33 -69.0%
Earnings Power Value Intrinsic $0.72 -78.7%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $1.69 -60.7% $0.23 -84.6%
PWERM Option-Based $4.34 +1.0% $0.22 -80.1%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for IOVA vs IVVD — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

IOVA vs IVVD — Which Stock Is More Undervalued?

IOVA scores higher with a 5.1/10 quality rating vs IVVD's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Iovance Biotherapeutics, Inc. (IOVA) and Invivyd, Inc. (IVVD) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

IOVA currently trades at $4.30 with a QOC of 5.1/10, while IVVD trades at $1.13 with a QOC of 4.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).